Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
Brandon Weiss, Leor Roseman, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, David Erritzøe
International Journal of Mental Health and Addiction March 7, 2024 DOI: 10.1007/s11469-024-01253-9 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Phase 2, double-blind, randomized, active comparator controlled trial Peer reviewed |
|---|---|
| Population | Patients with moderate-to-severe major depressive disorder |
| Interventions | Psilocybin Therapy Escitalopram Treatment |
| Duration | 6-week trial period |
| Topics | Depression Ego dissolution Mystical experience Psilocybin |
| Keywords | Psilocybin therapy psilocybin Depressive symptoms Antidepressant responses Successful treatment Acute mental states Emotional breakthrough Intense music reactions Acute psychological experiences |
| Citations | 26 |
| Key findings | Mystical experience and ego dissolution uniquely mediated the effect of psilocybin therapy versus escitalopram on depressive response, and higher levels of these experiences were associated with greater antidepressant response. |
Abstract
Abstract The mechanisms by which Psilocybin Therapy (PT) improves depression remain an important object of study, with scientists actively exploring acute psychological experiences and neurobiological processes as candidates. In a phase 2, double-blind, randomized, active comparator controlled trial involving patients with moderate-to-severe major depressive disorder, we investigated whether acute psychological experiences could meaningfully account for the unique efficacy of PT versus Escitalopram Treatment over a core 6-week trial period. An exploratory-factor-analysis-derived single-factor of depression was used as the outcome. Among a comprehensive set of acute experiences related to psilocybin, so-called “mystical experience” and “ego dissolution” were unique in mediating the effect of treatment condition on depressive response with high specificity. Higher reported levels of mystical experience, emotional breakthrough, and intense responses to music-listening were furthermore associated with greater antidepressant response. These results provide qualified support for the causal mechanistic role of acute psychological experiences in the treatment of depression via PT.
Comparable studies
Other randomized controlled trials on psilocybin for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety | 2016 | Randomized controlled trial | n = 51 |
| Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression | 2016 | Double-blind, placebo-controlled, crossover trial | n = 29 |
| Trial of Psilocybin versus Escitalopram for Depression Selected group of patients with depression | 2021 | Randomized controlled trial | |
| Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder Adults aged 21 to 75 years with major depressive disorder, not currently using... | 2020 | Randomized controlled trial | n = 24 |
| Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. Adults with treatment-resistant depression | 2022 | Phase 2 double-blind randomized controlled trial | n = 233 |
Citations in the library
Cited by 28
- Considering distinct positive emotions in psychedelic science. International Review of Psychiatry December 1, 2024
- Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis Therapeutic Advances in Psychopharmacology September 1, 2025
- Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories. Progress in Neuro-Psychopharmacology and Biological Psychiatry April 2, 2025
- The emotional architecture of the psychedelic brain Trends in Cognitive Sciences August 18, 2025
- What is needed for the roll-out of psychedelic treatments? Current Opinion in Psychiatry July 1, 2024
and 23 more in the library
Cites 81
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
and 76 more in the library